Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes | Zendy

Pierre Amarenco | Zendy; Oscar Benavente | Zendy; Larry B. Goldstein | Zendy; Alfred Callahan | Zendy; Henrik Sillesen | Zendy; Michael G. Hennerici | Zendy; Steve Gilbert | Zendy; Amy E. Rudolph | Zendy; Lisa Simunovic | Zendy; Justin A. Zivin | Zendy; K.M.A. Welch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes

Author(s) -

Pierre Amarenco,

Oscar Benavente,

Larry B. Goldstein,

Alfred Callahan,

Henrik Sillesen,

Michael G. Hennerici,

Steve Gilbert,

Amy E. Rudolph,

Lisa Simunovic,

Justin A. Zivin,

K.M.A. Welch

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.108.534107

Subject(s) - medicine , stroke (engine) , reduction (mathematics) , cardiology , physical therapy , geometry , mathematics , mechanical engineering , engineering

The SPARCL trial showed that atorvastatin 80 mg/d reduces the risk of stroke and other cardiovascular events in patients with recent stroke or transient ischemic attack (TIA). We tested the hypothesis that the benefit of treatment varies according to index event stroke subtype.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research